NEW YORK (GenomeWeb News) – Shares of DeCode Genetics climbed more than 40 percent today following an announcement that the company had discovered two SNPs associated with the risk of basal cell carcinoma, the most common cancer among people of European ancestry.
 
The boost in DeCode’s shares, which opened at $.36 today and were priced at $.54 in mid-afternoon trading, outpaced a broad rally in the capital markets following a massive sell-off in recent weeks.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.